CovalX
CovalX AG was originally a Zürich, Switzerland-based company that developed High Mass MALDI detection systems, a mass spectrometric platform for characterizing therapeutic proteins.
Origins
A spin-off of the Swiss Federal Institute of Technology, CovalX was founded by Ryan Wenzel, Alexis Nazabal, and Urs Matter in 2005 as CovalX GmbH and was converted in January 2007 to AG status to allow additional investors into the company.In 2011, CovalX founded a wholly owned US subsidiary called CovalX Instruments Incorporated located in the Boston area. They began manufacturing and testing the mass spectrometry instruments based on their proprietary technique as well as sales and support for their hardware products.
CovalX developed and patented a technology platform based on mass spectrometry allowing ultra-fast and direct analysis of protein-protein interactions in solution, called High Mass MALDI. The technology has been named on many patents including:
- Abbvie: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.
- Aix Marseille Universite: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.
Applications:
Notable Citations:
CovalX and its proprietary platform has been cited in many leading publications:
https://patents.google.com/patent/US20230183369A1
https://patents.google.com/patent/AU2021270458A1
https://patents.google.com/patent/US20220162305A1/en
https://www.mass-spec-capital.com/organisation/covalx-instruments-inc-north-america-group-saugus-massachusetts-2001-26645.html